[go: up one dir, main page]

MX2014005399A - Metodos para tratar gota en sub-poblaciones de pacientes. - Google Patents

Metodos para tratar gota en sub-poblaciones de pacientes.

Info

Publication number
MX2014005399A
MX2014005399A MX2014005399A MX2014005399A MX2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A
Authority
MX
Mexico
Prior art keywords
methods
treating gout
patient subpopulations
subject
subpopulations
Prior art date
Application number
MX2014005399A
Other languages
English (en)
Other versions
MX354846B (es
Inventor
Brian Edward Lavan
Gopal Chandra Saha
Brian K Roberts
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014005399A publication Critical patent/MX2014005399A/es
Publication of MX354846B publication Critical patent/MX354846B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En una modalidad, la presente solicitud describe un método para reducir el nivel de ácido úrico en suero en un sujeto con una función renal dañada, que comprende administrar a los sujetos un compuesto de la Fórmula (I), como aquí se describe.
MX2014005399A 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes. MX354846B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
MX2014005399A true MX2014005399A (es) 2015-04-08
MX354846B MX354846B (es) 2018-03-22

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005399A MX354846B (es) 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes.

Country Status (14)

Country Link
EP (1) EP2775835A4 (es)
JP (1) JP6047172B2 (es)
KR (1) KR101848122B1 (es)
CN (1) CN104066323A (es)
AU (1) AU2011380509B2 (es)
BR (1) BR112014010693A2 (es)
CA (1) CA2859689C (es)
CL (1) CL2014001156A1 (es)
IL (1) IL232385A (es)
MX (1) MX354846B (es)
NZ (1) NZ624714A (es)
SG (1) SG11201402027PA (es)
WO (1) WO2013066352A1 (es)
ZA (1) ZA201403574B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512948A (ja) * 2012-04-13 2015-04-30 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN105851522A (zh) * 2014-07-25 2016-08-17 许伟琦 一种防止尿路结石的饲料
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
CN111246852A (zh) * 2017-10-26 2020-06-05 大塚制药株式会社 含有磷酸肌醇的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
ES2513390T3 (es) * 2007-11-27 2014-10-27 Ardea Biosciences, Inc. Nuevos compuestos y composiciones, y métodos de uso

Also Published As

Publication number Publication date
AU2011380509B2 (en) 2016-05-19
NZ624714A (en) 2016-01-29
EP2775835A4 (en) 2015-07-29
SG11201402027PA (en) 2014-09-26
CA2859689C (en) 2018-05-22
AU2011380509A1 (en) 2014-05-29
ZA201403574B (en) 2015-11-25
JP2014532759A (ja) 2014-12-08
CA2859689A1 (en) 2013-05-10
CN104066323A (zh) 2014-09-24
EP2775835A1 (en) 2014-09-17
IL232385A (en) 2017-10-31
CL2014001156A1 (es) 2015-01-16
KR20140123927A (ko) 2014-10-23
IL232385A0 (en) 2014-06-30
MX354846B (es) 2018-03-22
WO2013066352A1 (en) 2013-05-10
JP6047172B2 (ja) 2016-12-21
KR101848122B1 (ko) 2018-04-11
BR112014010693A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12013501718A1 (en) Production method of optically active dihydrobenzofuran derivative
PH12013502144A1 (en) Multiple myeloma treatment
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
BR112013005810A2 (pt) métodos para reduzir a concentração de lactato no sangue
GEP20166448B (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
MX2014004920A (es) Nuevos derivados de pirazina.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
PH12014500990A1 (en) Methods for treating gout flares
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
FR2980708B1 (fr) Composition comprenant un gallotannin
MX354846B (es) Metodos para tratar gota en sub-poblaciones de pacientes.
HUE040484T2 (hu) Eljárás (3S,3S')4,4'-diszulfándiilbisz(3-aminobután-1-szulfonsav) elõállítására
GB201107985D0 (en) Process
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
MY172619A (en) Method for refining quinolinic acid
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
HUE036037T2 (hu) (3S,3S')4,4'-Diszulfándiil-bisz(3-aminobután-1-szulfonsav), azaz ABSD, L-lizinnel képezett kristályos alakja
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2012003290A (es) Composicion para reducir el nivel de acido urico en la sangre.

Legal Events

Date Code Title Description
FG Grant or registration